Akèy › Limfòm Burkitt
Etid klinik pou Limfòm Burkitt ap rekrite nan Etazini
63 etid pou Limfòm Burkitt ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX21 etid
- Milwaukee, WI16 etid
- Philadelphia, PA16 etid
- New York City, NY14 etid
- Chicago, IL13 etid
- Seattle, WA12 etid
- Cincinnati, OH12 etid
- Atlanta, GA11 etid
- Boston, MA10 etid
- Los Angeles, CA10 etid
- Durham, NC10 etid
- Kansas City, MO10 etid
- Aurora, CO10 etid
- Washington, DC9 etid
- Minneapolis, MN9 etid
- Baldwin Park, CA9 etid
- Orange, CA9 etid
- Baltimore, MD8 etid
- San Francisco, CA8 etid
- Buffalo, NY8 etid
- Columbus, OH8 etid
- Portland, OR8 etid
- Nashville, TN8 etid
- Ann Arbor, MI8 etid
- Tampa, FL7 etid
- Dallas, TX7 etid
- Providence, RI7 etid
- Richmond, VA7 etid
- Clifton, NJ7 etid
- Jacksonville, FL7 etid
- Cleveland, OH7 etid
- Salt Lake City, UT7 etid
- San Antonio, TX7 etid
- Greenburgh, NY7 etid
- Grand Rapids, MI7 etid
- Oklahoma City, OK7 etid
- Birmingham, AL7 etid
- Mountain View, CA6 etid
- Denver, CO6 etid
- The Bronx, NY6 etid
Pa eta
- Alabama7 etid
- Arizona7 etid
- Arkansas5 etid
- Ayiti5 etid
- Colorado13 etid
- Connecticut7 etid
- Delaware7 etid
- Distrik Columbia5 etid
- Florid15 etid
- Georgia11 etid
- Idaho6 etid
- Illinois13 etid
- Indiana6 etid
- Iowa7 etid
- Kalifòni20 etid
- Kansas6 etid
- Kentucky5 etid
- Lwizyàn4 etid
- Main4 etid
- Maryland11 etid
- Massachusetts10 etid
- Michigan10 etid
- Minnesota10 etid
- Mississippi4 etid
- Missouri8 etid
- Nebraska5 etid
- Nevada6 etid
- New Hampshire4 etid
- New Jersey8 etid
- New Mexico3 etid
- New York20 etid
- North Carolina13 etid
- North Dakota5 etid
- Ohio17 etid
- Oklahoma7 etid
- Oregon8 etid
- Pennsylvania18 etid
- Rhode Island7 etid
- South Carolina5 etid
- South Dakota5 etid
- Tennessee10 etid
- Texas24 etid
- Utah7 etid
- Vermont3 etid
- Virginia7 etid
- Washington12 etid
- West Virginia3 etid
- Wisconsin17 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT03223610A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
366 Days – 46 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06144606Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Ap rekriteFaz 3
Laj 1 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07223021A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Ap rekriteFaz 1
Laj 0 a 18 · Tout sèks · Mizajou Sep 16, 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Ap rekriteFaz 1/2
31 Days – 30 Years · Tout sèks · Mizajou Sep 14, 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Ap rekriteFaz 3
Laj 18 a 39 · Tout sèks · Mizajou Sep 2, 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 25, 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06137118Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Ap rekriteFaz 2
Laj 15 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 a 81 · Tout sèks · Mizajou Aug 6, 2026 · NCT05990465Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07069699Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.